A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease

European Journal of Haematology

Volumn 87, Issue 5, 2011, Pages 461-463

  Roug, Anne Stidsholt ^a   Nyvold, Charlotte Guldborg ^a   Juhl Christensen, Caroline ^a   Christensen, Mariann ^a   Schnittger, Susanne ^b   Hokland, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

Acute myeloid leukemia; JAK2 V617F; Myeloproliferative neoplasms; NPM1

Indexed keywords

ACETYLSALICYLIC ACID; CD33 ANTIGEN; CYTARABINE; GENOMIC DNA; IDARUBICIN; JANUS KINASE 2; MICROSOMAL AMINOPEPTIDASE; NUCLEOPHOSMIN; RNA; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLADDER CANCER; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; BONE MARROW; BONE MARROW BIOPSY; BONE MARROW DEPRESSION; BONE PAIN; CANCER DIAGNOSIS; CANCER SURGERY; CASE REPORT; DISEASE COURSE; DNA EXTRACTION; FEMALE; FLOW CYTOMETRY; GEL ELECTROPHORESIS; GENE MUTATION; HUMAN; HYPERVISCOSITY SYNDROME; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MEGAKARYOCYTE; MOLECULAR BIOLOGY; MYCOSIS; MYELOBLAST; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RNA EXTRACTION;

ELECTROPHORESIS, CAPILLARY; FEMALE; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION;

EID: 80054049935     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01669.x     Document Type: Article

References (12)

1. Plo I, Nakatake M, Malivert L, de Villartay J-P, Giraudier S, Villeval J-L, Wiesmuller L, Vainchenker W. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008;112:1402-12.
2. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664-70.
3. Beer PA, Delhommeau F, LeCouédic J-P, et al. Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 2010;115:2891-900.
4. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 2010;24:1574-9.
5. Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006;108:3548-55.
6. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, Haferlach T, Hiddemann W, Falini B. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005;106:3733-9.
7. Pasqualucci L, Li S, Meloni G, et al. NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin? Leukemia 2008;22:1459-63.
8. Schnittger S, Bacher U, Haferlach C, Alpermann T, Dicker F, Sundermann J, Kern W, Haferlach T. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms. Leukemia 2011;4:615-21.
9. Larsen TS, Christensen JH, Hasselbalch HC, Pallisgaard N. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders. Br J Haematol 2007;136:745-51.
10. Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, Haferlach C, Haferlach T. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009;114:2220-31.
11. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, Ehninger G. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006;107:4011-20.
12. Falini B, Martelli MP, Mecucci C, et al. Cytoplasmic mutated nucleophosmin is stable in primary leukemic cells and in a xenotransplant model of NPMc+ acute myeloid leukemia in SCID mice. Haematologica 2008;93:775-9.